{"nctId":"NCT05040971","briefTitle":"Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes","startDateStruct":{"date":"2021-09-06","type":"ACTUAL"},"conditions":["Obesity"],"count":207,"armGroups":[{"label":"Semaglutide","type":"EXPERIMENTAL","interventionNames":["Drug: Semaglutide 2.4 mg"]},{"label":"Placebo (semaglutide)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Semaglutide 2.4 mg","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female aged greater than or equal to 18 years at the time of signing informed consent.\n* BMI greater than or equal to 30.0 kg/m\\^2\n* Prediabetes defined as at least one of the following:\n\n  * HbA1c between 6.0 and 6.4 percent (42 and 47 mmol/mol) (both inclusive) as measured by central laboratory at screening.\n  * FPG between 5.5 and 6.9 mmol/L (99 and 125 mg/dL) (both inclusive) as measured by central laboratory at screening.\n\nExclusion Criteria:\n\n* History of type 1 or type 2 diabetes.\n* Treatment with glucose-lowering agent(s) within 90 days before screening.\n* HbA1c greater than or equal to 6.5 percent (greater than or equal to 48 mmol/mol) as measured by central laboratory at screening.\n* FPG greater than or equal to 7.0mmol/L (126 mg/dL) as measured by central laboratory at screening.\n\nA self-reported change in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records.\n\n* Treatment with any medication for the indication of obesity within the past 90 days before screening.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Body Weight (Percentage [%])","description":"Change in body weight from randomisation (week 0) to end of treatment (week 52) is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.4","spread":"7.9"},{"groupId":"OG001","value":"-2.7","spread":"4.3"}]}]}]},{"type":"PRIMARY","title":"Participants With Change to Normoglycemia","description":"Number of participants in glycaemic categories, \"normoglycaemia, pre-diabetes and type 2 diabetes\" at Week 52 are presented. These categories were set as per the following criteria: 1) Normoglycaemia: glycosylated haemoglobin (HbA1c) lesser than (\\<) 6.0 percentage (%) and fasting plasma glucose (FPG) lesser than (\\<) 5.5 millimoles per liter (mmol/L). 2) Pre-diabetes: 6.0% lesser than or equal (≤) HbA1c lesser than (\\<) 6.5% or 5.5 mmol/L lesser than or equal (≤) FPG lesser than (\\<) 7.0 mmol/L or non-verified type 2 diabetes. 3) Type 2 diabetes: HbA1c greater than or equal (≥) 6.5% or FPG greater than or equal (≥) 7.0 mmol/L.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"103","spread":null},{"groupId":"OG001","value":"9","spread":null}]},{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"53","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Glycosylated Haemoglobin (HbA1c)","description":"Change in glycosylated haemoglobin (HbA1c) from randomisation (week 0) to end of treatment (week 52) is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.3"},{"groupId":"OG001","value":"0.1","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose (FPG)","description":"Change in fasting plasma glucose (FPG) from randomisation (week 0) to end of treatment (week 52) is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"0.6"},{"groupId":"OG001","value":"-0.3","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Change in Waist Circumference","description":"Change in waist circumference from randomisation (week 0) to end of treatment (week 52) is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.6","spread":"8.7"},{"groupId":"OG001","value":"-2.8","spread":"5.4"}]}]}]},{"type":"SECONDARY","title":"Change in Systolic Blood Pressure","description":"Change in systolic blood pressure from randomisation (week 0) to end of treatment (week 52) is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9","spread":"13"},{"groupId":"OG001","value":"-1","spread":"13"}]}]}]},{"type":"SECONDARY","title":"Change in Triglycerides (Millimoles Per Liter [mmol/L]) - Ratio to Baseline","description":"Change in triglycerides (measured in mmol/L) from randomisation (week 0) to end of treatment (week 52) is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.80","spread":"36.4"},{"groupId":"OG001","value":"0.96","spread":"30.6"}]}]}]},{"type":"SECONDARY","title":"Change in Total Cholesterol (mmol/L) - Ratio to Baseline","description":"Change in total cholesterol (measured in mmol/L) from randomisation (week 0) to end of treatment (week 52) is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.94","spread":"16.1"},{"groupId":"OG001","value":"1.01","spread":"15.7"}]}]}]},{"type":"SECONDARY","title":"Change in High Density Lipoprotein (HDL) Cholesterol (mmol/L) - Ratio to Baseline","description":"Change in high density lipoprotein (HDL) cholesterol (measured in mmol/L) from randomisation (week 0) to end of treatment (week 52) is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.02","spread":"12.4"},{"groupId":"OG001","value":"0.99","spread":"11.7"}]}]}]},{"type":"SECONDARY","title":"Change in Low Density Lipoprotein (LDL) Cholesterol (mmol/L) - Ratio to Baseline","description":"Change in low density lipoprotein (LDL) cholesterol (measured in mmol/L) from randomisation (week 0) to end of treatment (week 52) is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.93","spread":"26.6"},{"groupId":"OG001","value":"1.03","spread":"23.6"}]}]}]},{"type":"SECONDARY","title":"Change in Very Low Density Lipoprotein (VLDL) Cholesterol (mmol/L) - Ratio to Baseline","description":"Change in very low density lipoprotein (VLDL) cholesterol (measured in mmol/L) from randomisation (week 0) to end of treatment (week 52) is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.80","spread":"36.5"},{"groupId":"OG001","value":"0.96","spread":"30.7"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight (Kilogram [Kg])","description":"Change in body weight from randomisation (week 0) to end of treatment (week 52) is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.8","spread":"9.3"},{"groupId":"OG001","value":"-2.8","spread":"5.0"}]}]}]},{"type":"SECONDARY","title":"Participants Achieving Body Weight Reduction Greater Than or Equal (≥) 5% (Yes/No)","description":"Participants who achieved body weight reduction greater than or equal to 5% (Yes/No) at week 52 is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"111","spread":null},{"groupId":"OG001","value":"17","spread":null}]},{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants Achieving Body Weight Reduction Greater Than or Equal (≥) 10% (Yes/No)","description":"Participants who achieved body weight reduction greater than or equal to 10% (Yes/No) at week 52 is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"5","spread":null}]},{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"61","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants Achieving Body Weight Reduction Greater Than or Equal (≥) 15% (Yes/No)","description":"Participants who achieved body weight reduction greater than or equal to 15% (Yes/No) at week 52 is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants Achieving Body Weight Reduction Greater Than or Equal (≥) 20% (Yes/No)","description":"Participants who achieved body weight reduction greater than or equal to 20% (Yes/No) at week 52 is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"66","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Pulse","description":"Change in pulse from randomisation (week 0) to end of treatment (week 52) is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":"10"},{"groupId":"OG001","value":"0","spread":"7"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":138},"commonTop":["COVID-19","Nausea","Constipation","Diarrhoea","Vomiting"]}}}